M&A Deal Summary

Archimica Acquires Archimica

On February 1, 2011, Archimica acquired life science company Archimica from TowerBrook Capital Partners and Aisling Capital

Acquisition Highlights
  • This is Archimica’s 1st transaction in the Life Science sector.
  • This is Archimica’s 1st transaction in the United States.
  • This is Archimica’s 1st transaction in Virginia.

M&A Deal Summary
Date 2011-02-01
Target Archimica
Sector Life Science
Buyer(s) Archimica
Sellers(s) TowerBrook Capital Partners
Aisling Capital
Deal Type Add-on Acquisition

Target

Archimica

Origgio, Virginia, United States
Archimica is a privately held pharmaceutical fine chemical company that combines world-scale chemical manufacturing experience with a history of pharmaceutical commercialization that stretches back over 40 years.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Archimica

Lodi, Italy
Category Company
Founded 1946
Sector Life Science
Revenue 245M USD (2015)
DESCRIPTION

Archimica offers small- to large-scale commercial manufacturing as well as analytical support for the global biopharmaceutical market. The company is specialized in custom synthesis and the manufacture of active pharmaceutical ingredients (“APIs”). Archimica was founded in 1946 and is based in Lodi, Italy.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Virginia) 1 of 1
Country (United States) 1 of 1
Year (2011) 1 of 1

Seller(S) 2

SELLER

TowerBrook Capital Partners

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2001
PE ASSETS 17.4B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

TowerBrook Capital Partners is a private equity firm focused on leveraged buyouts, leveraged build-ups and distressed situation investments throughout North America and Europe. TowerBrook prefers control-oriented investments and actively pursues complex situations that other firms may avoid. Target sectors include consumer services, distribution, beverages, pharmaceuticals, media, technology, communications, software, and healthcare. TowerBrook Capital Partners was established in 2001 and is headquartered in New York City.

DEAL STATS #
Overall 14 of 45
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 6 of 21
State (Virginia) 1 of 1
Country (United States) 10 of 24
Year (2011) 2 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-01-04 DISA

Houston, Texas, United States

DISA is specializes in providing a comprehensive suite of employee testing, screening, and compliance management solutions to a diverse set of end markets. DISA was founded in 1986 and is based in Houston, Texas.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-02-17 Phase Eight

LONDON, United Kingdom

Phase Eight offers a range of evening wear, bridalwear and accessories aimed at the 35- to 55-year-old woman. It has 107 stores and 203 concessions throughout the U.K. and Ireland as well as 15 stores and 113 concessions in 16 international markets including Europe, the Middle East and Asia.

Buy -
SELLER

Aisling Capital

New York, New York, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2000
PE ASSETS 1.8B USD
Size Large
Type Sector Focused
DESCRIPTION

Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.

DEAL STATS #
Overall 15 of 41
Sector (Life Science) 13 of 32
Type (Add-on Acquisition) 14 of 24
State (Virginia) 1 of 1
Country (United States) 15 of 41
Year (2011) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-05-28 Aton Pharma

Lawrenceville, New Jersey, United States

Aton Pharma, Inc. is a specialty pharmaceutical company providing unique medicines to patients around the world.With 11 products on the market, 8 in the pipeline, and sales in over 30 countries, we are a global leader in providing medically essential treatments for serious and potentially life-threatening medical conditions. Our products address 2 areas — ophthalmic and orphan drug (rare disease) markets.

Sell $318M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-07-01 Miramar Labs

Sunnyvale, California, United States

Miramar Labs is a privately owned medical device company dedicated to launching the next generation energy modality to treat dermatologic medical conditions. Miramar Labs was founded in 2006 and is based in Sunnyvale, California.

Buy -
Mergr

Product

Company

Legal